ConverGene Pharma

ConverGene Pharma is a clinical-stage biotechnology company specializing in the development of epigenetic-targeted therapies for oncology. The company's research focuses on the Bromodomain and Extra-Terminal (BET) family of proteins, which are key regulators of oncogene expression. Its lead clinical candidate, CG-1556, is a small molecule BET inhibitor designed to treat various hematologic malignancies and advanced solid tumors. By utilizing a proprietary discovery platform, ConverGene aims to develop highly selective inhibitors with improved safety and efficacy profiles compared to first-generation epigenetic drugs. The company operates out of Gaithersburg, Maryland, and Suzhou, China, positioning itself for international clinical development.